NASDAQ · IMDX
Healthcare · Biotechnology
$3.92
Down-$0.03 (-0.76%)
Updated Sep 26, 2026, 9:56 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IMDX closed at $3.92 after 20 trading sessions, down 5.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $3.99 | $4.002 | $3.76 | $3.92 | 313.5K |
| Sep 24, 2026 | $3.88 | $4.00 | $3.70 | $3.95 | 274.27K |
| Sep 23, 2026 | $4.08 | $4.08 | $3.65 | $3.91 | 597.26K |
| Sep 22, 2026 | $4.04 | $4.26 | $4.025 | $4.14 | 309.27K |
| Sep 21, 2026 | $4.09 | $4.13 | $3.84 | $4.01 | 253.95K |
| Sep 18, 2026 | $3.90 | $4.10 | $3.77 | $4.00 | 317.92K |
| Sep 17, 2026 | $3.67 | $3.98 | $3.51 | $3.95 | 197.74K |
| Sep 16, 2026 | $4.03 | $4.205 | $3.50 | $3.58 | 303.08K |
| Sep 15, 2026 | $3.99 | $4.24 | $3.77 | $4.02 | 213.7K |
| Sep 14, 2026 | $4.08 | $4.22 | $3.91 | $4.02 | 526.83K |
| Sep 11, 2026 | $4.06 | $4.2275 | $3.94 | $4.20 | 173.83K |
| Sep 10, 2026 | $4.04 | $4.15 | $3.91 | $3.98 | 119.47K |
| Sep 9, 2026 | $4.26 | $4.26 | $4.0125 | $4.10 | 188.81K |
| Sep 8, 2026 | $4.13 | $4.3213 | $3.85 | $4.27 | 212.82K |
| Sep 4, 2026 | $4.10 | $4.18 | $3.99 | $4.13 | 183.52K |
| Sep 3, 2026 | $3.98 | $4.22 | $3.85 | $4.12 | 307.82K |
| Sep 2, 2026 | $3.81 | $4.04 | $3.71 | $4.01 | 80.82K |
| Sep 1, 2026 | $3.86 | $3.99 | $3.74 | $3.84 | 128.12K |
| Aug 31, 2026 | $4.10 | $4.115 | $3.88 | $3.92 | 102.4K |
| Aug 28, 2026 | $4.245 | $4.48 | $4.10 | $4.13 | 81.03K |
The latest Smart Investors Daily articles mentioning IMDX.
IMDX research
Company profile and research snapshot.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Aug 18, 2026 | Needham | Buy | — |
| Feb 17, 2026 | Lake Street | Buy | — |
| Nov 11, 2025 | Needham | Buy | — |
| Aug 18, 2025 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 21, 2026
As previously reported, Insight Molecular Diagnostics Inc. (the "Company" or "iMDx") entered into an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and
Yahoo · Sep 2, 2026
NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York. Event: Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” ConferenceWho: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea JamesDate: Thursday, September 10, 2026Location: Metropolit
Benzinga · Aug 24, 2026
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
Benzinga · Aug 24, 2026
Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMDX.
